Therapies on the Horizon for Diabetic Kidney Disease. (Q38605099)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26458382%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

title

Therapies on the Horizon for Diabetic Kidney Disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26458382%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Sadaf S Khan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26458382%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Susan E Quaggin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26458382%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

1 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26458382%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

published in

Current diabetes report

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26458382%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26458382%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26458382%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26458382%20AND%20SRC:MED&resulttype=core&format=json

Non-proteinuric diabetic nephropathy

26 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Mechanisms of diabetic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Temporal trends in the prevalence of diabetic kidney disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Combined angiotensin inhibition for the treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

The Nrf2 pathway in the progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

The role of protein kinase C activation and the vascular complications of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

The effect of ruboxistaurin on nephropathy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Pirfenidone for diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Avosentan for overt diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Orchestral actions of angiopoietin-1 in vascular regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Angiopoietin-1 is essential in mouse vasculature during development and in response to injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Oxidative Stress and Diabetic Complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Suppressors of cytokine signaling abrogate diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Co-regulation of Gremlin and Notch signalling in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Role of the JAK/STAT signaling pathway in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Antiproteinuric Effect of Chemokine C-C Motif Ligand 2 Inhibition in Subjects with Acute Proliferative Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0685-3

Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy

21 January 2018

1 reference

12 December 2020

Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes

1 reference

12 December 2020

US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States.

1 reference

12 December 2020

Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease

1 reference

12 December 2020

Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy

1 reference

12 December 2020

Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats

1 reference

12 December 2020

Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats.

1 reference

12 December 2020

Increased glomerular alpha 1 (IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment

1 reference

12 December 2020

Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes

1 reference

12 December 2020

Increased expression of heparanase in overt diabetic nephropathy

1 reference

12 December 2020

10.1007/S11892-015-0685-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26458382%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

26 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26458382%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

PubMed publication ID

26458382

1 reference